In this prospective study, we assessed biomarkers of inflammation (IL-6 and SAA) from the
serum of 120 COVID-19 patients, of whom 70 had chronic kidney disease. All the samples …

Abstract Background Coronavirus disease 2019 (COVID-19) was announced in early
December 2019. The pandemic situation is declared. This study aimed to evaluate the role …

Abstract Background: Interleukin-6 (IL-6) has been known to be involved in immune
regulation, inflammatory response, and metabolism. It is also recognized as the major cause …

Objectives An excessive inflammatory response to SARS-CoV-2 is thought to be a major
cause of disease severity in COVID-19. The aim herein was to determine the prognostic …

The prognostic value of interleukin-6 in COVID-19 needs to be clarified. In this retrospective
study, COVID-19 patients treated in Renmin Hospital of Wuhan University from Jan 7 to Feb …

COVID-19 has caused devastating effects worldwide ever since its origin in December 2019.
IL-6 is one of the chief markers used in the management of COVID-19. We conducted a …

Objectives Persistent severe acute kidney injury (PS-AKI) is associated with poor clinical
outcomes. Our study attempted to evaluate the diagnostic value of chemokines for early …

The COVID-19 pandemic poses global healthcare challenges due to its unpredictable
clinical course. The aim of this study is to identify inflammatory biomarkers and other routine …

Predictors of mortality, an important factor to guide management in COVID-19 patients, have
not been fully understood. The common laboratory test for assessing severity in COVID-19 …

Background The infection caused by SARS CoV-2 has been postulated to induce a cytokine
storm syndrome that results in organ failure and even death in a considerable number of …